PubRank

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

Clinical Trial ID NCT00089791

PubWeight™ 44.56‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00089791

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 13.57
2 Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2012 2.81
3 Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012 1.92
4 Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012 1.78
5 Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012 1.77
6 Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010 1.74
7 Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 2013 1.66
8 The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013 1.60
9 Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 2012 1.54
10 Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 2013 1.47
11 Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011 1.40
12 Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011 1.32
13 The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 2015 1.29
14 Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011 1.27
15 Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res 2011 1.05
16 Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res 2014 1.01
17 Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 2015 0.95
18 Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone 2013 0.87
19 Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2011 0.87
20 Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 2012 0.85
21 RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 2014 0.85
22 Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporos Int 2011 0.85
23 Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom 2012 0.80
24 Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence. Int J Womens Health 2015 0.79
25 Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 2011 0.79
26 Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. Osteoporos Int 2012 0.78
27 Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis. Osteoporos Int 2015 0.75
28 Aortic stenosis: insights on pathogenesis and clinical implications. J Geriatr Cardiol 2016 0.75
Next 100